OncoMatch/Clinical Trials/NCT07825064
Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
Official title: A Phase II, Single Arm, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone in Patients With Multiple Myeloma Who Have Received a Prior BCMA-Targeting CAR T-Cell Therapy
Is NCT07825064 recruiting? Yes, currently enrolling (Oct 2026). This Phase 2 trial studies multiple treatments including Cevostamab and Pomalidomide for multiple myeloma.
Treatment: Cevostamab · Pomalidomide · Dexamethasone · Tocilizumab — The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) in patients with multiple myeloma (MM) who have received one to four prior lines of therapy and have been exposed to an anti-cluster of differentiation 38 (CD38) antibody, lenalidomide, a proteasome inhibitor (PI) and a B cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T-cell therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Endocrine / hormonal
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: CAR-T cell therapy targeting BCMA
prior B-cell maturation antigen (BCMA)-targeting Chimeric Antigen Receptors (CAR) T-cell therapy
Must have received: anti-CD38 therapy
received anti-cluster of differentiation 38 (CD38) therapy
Must have received: proteasome inhibitor
received ... a proteasome inhibitor (PI)
Must have received: immunomodulatory agent (lenalidomide)
received ... lenalidomide in any prior line
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07825064 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received CAR-T cell therapy targeting BCMA and anti-CD38 therapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages